| Bassan, Renato |
| Active, not recruiting | 3 | 245 | Europe, Canada, Japan, US, RoW | Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone | Takeda | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | 08/22 | 07/27 | | |
|
|
| Recruiting | 3 | 172 | Europe | Cytarabine, Daunorubicin, Midostaurin, Cytarabine HD | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Myeloid Leukemia With FLT3/ITD Mutation | 12/22 | 08/25 | | |
NCT04168502: Gemtuzumab Chemotherapy MRD Levels; Glasdegib Post-transplant, Adult Untreated, de Novo, Fav Interm Risk AML |
|
|
| Recruiting | 3 | 414 | Europe | Glasdegib, Gemtuzumab Ozogamicin | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Myeloid Leukemia | 04/24 | 04/27 | | |
| Recruiting | 3 | 430 | Europe | Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses | Fondazione Italiana Linfomi ONLUS, GRADE Onlus | Diffuse Large B-Cell Lymphoma, Elderly Patients | 09/25 | 09/30 | | |
CLL17, NCT04608318 / 2019-003854-99: Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) |
|
|
| Active, not recruiting | 3 | 897 | Europe, RoW | Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro | German CLL Study Group, Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research (SAKK), Cancer Trials Ireland, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), Grupo Español de Leucemia Linfocítica Crónica (GELLC), The Israeli CLL Study Group (ICLLSG) | Chronic Lymphoid Leukemia | 03/27 | 03/27 | | |
ALL2820, NCT04722848: Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL |
|
|
| Recruiting | 3 | 236 | Europe | Ponatinib + Blinatumomab, Chemotherapy + Imatinib | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult, Philadelphia-Positive ALL | 09/27 | 09/27 | | |
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma |
|
|
| Recruiting | 3 | 602 | Europe | Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B) | Fondazione Italiana Linfomi - ETS | Follicular Lymphoma | 07/28 | 07/30 | | |
| Recruiting | 2a | 76 | Europe | Inotuzumab Ozogamicin (IO) | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Lymphoid Leukemia | 11/22 | 11/22 | | |
NCT04475731: Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse |
|
|
| Recruiting | 2 | 67 | Europe | Ponatinib | Gruppo Italiano Malattie EMatologiche dell'Adulto | Philadelphia-Positive ALL, Acute Lymphoblastic Leukemia, in Relapse | 11/24 | 11/24 | | |
| Active, not recruiting | 2 | 37 | Europe | Copanlisib, ALIQOPA | Fondazione Italiana Linfomi - ETS | Diffuse Large B-cell Lymphoma | 08/24 | 08/24 | | |
| Active, not recruiting | 2 | 149 | Europe | Chemotherapy + Blinatumomab | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Lymphoid Leukemia, Philadelphia Chromosome-Negative B-Cell Precursor | 02/24 | 02/24 | | |
INO-CD22, NCT03898128: ItaliaN Observational Study of Patients With Acute Lymphoblastic Leukemia Treated With Anti-CD22 Immunoconjugate |
|
|
| Recruiting | N/A | 120 | Europe | Anti-CD22 Immunotoxin | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | Acute Lymphoblastic Leukemia | 06/21 | 09/21 | | |
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance |
|
|
| Recruiting | N/A | 250 | Europe | | Ospedale di Circolo - Fondazione Macchi | SARS-CoV-2 Infection, Hematological Malignancies | 10/22 | 10/22 | | |
GIMEMA 2320, NCT04589728: Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96 |
|
|
| Recruiting | N/A | 104 | Europe | Venetoclax plus HMA | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Myeloid Leukemia | 12/22 | 12/23 | | |
NCT03318770: Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia |
|
|
| Recruiting | N/A | 60 | Europe | Dasatinib and blinatumomab | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Lymphoblastic Leukemia | 05/24 | 05/24 | | |
NCT04582487: Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL |
|
|
| Recruiting | N/A | 32 | Europe | bone marrow and/or peripheral blood samples withdrawal | Gruppo Italiano Malattie EMatologiche dell'Adulto | T Acute Lymphoblastic Leukemia, Early T Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma, Etp All | 05/24 | 05/24 | | |
